• PDF / 169,383 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 72 Downloads / 223 Views

DOWNLOAD

REPORT

---

1 S

Programmed-cell-death-1-receptor-antagonists/rivoceranib Various toxicities: 3 case reports

In a retrospective, single-center study conducted from May 2018 to May 2019 involving 24 patients, 3 patients [ages and sexes not stated] were described, who developed liver function damage (1 patient), rash and pruritus (1 patient) and hand-foot syndrome (1 patient) during treatment with rivoceranib and an unspecified programmed cell death-1 inhibitor for gastric or esophagogastric junction cancer (GC/EGJC). The patients, who had GC/EGJC, started receiving treatment with an unspecified programmed cell death-1 inhibitor and rivoceranib [apatinib] 250mg. During treatment, the patients developed liver function damage in the form of elevated AST and ALT (1 patient), rash and pruritus (1 patient) and hand-foot syndrome (1 patient) as a treatment related adverse events [duration of treatments to reactions onset not stated]. All events were found to be grade 3 or 4 as per author’s assessment. The patients treatment with rivoceranib and an unspecified programmed cell death-1 inhibitor was discontinued [outcomes not stated]. Wei Q, et al. PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: A retrospective study. Translational Cancer Research 9: 5315-5322, No. 9, Sep 2020. Available from: URL: http://doi.org/10.21037/tcr-20-1333

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803518336

Reactions 5 Dec 2020 No. 1833